In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: March 2009

Executive Summary

Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries. March 2009 dealmaking highlights: BMS' worldwide ex-Japanese license to Nissan/Teijin's CV candidate NTC801 topped the alliance list in terms of potential deal value at $210mm. The remaining pharma alliances for March didn't even surpass $50mm in pre-commercial value. In M&As, the Big Pharma mega merger of Merck and Schering-Plough was the biggest news, in a deal valued around $42bn. Pharmaceutical financings were down by about $100mm compared with February, and Early VC rounds made up the majority of the $406mm raised. Funding for device firms, on the other hand, was up from last month to $297mm thanks to a strong showing of late venture financings.

You may also be interested in...



Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.

Medtronic Adds Smart Insulin Pen By Acquiring Companion Medical

The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery. 

Topics

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel